In particular, it has been demonstrated that Bcl-2 overexpression prevents prostate cancer cells from passing through apoptosis, prevents TRAIL-induced apoptosis in neuroblastoma, glioblastoma, and breast cancer cells, and gives tumor cells multidrug resistance [126,127]. This evidence concerns the gene BCL2 and neoplasm.